Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome
February 25, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
February 04, 2022 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors
December 27, 2021 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis
October 28, 2021 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference
October 26, 2021 09:31 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of ‘1104 in Allergic Disease in the UK
October 21, 2021 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK
July 30, 2021 08:30 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, July 30, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium
July 15, 2021 08:00 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces the Appointments of Marla S. Persky and Glen Giovannetti to its Board of Directors
July 01, 2021 08:30 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, July 01, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior...
Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
June 23, 2021 08:30 ET
|
Revolo Biotherapeutics
NEW ORLEANS and LONDON, June 23, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior...